Design, synthesis and antitumor evaluation of a new series of N-substituted-thiourea derivatives

Acta Pharmacologica Sinica

Volumn 27, Issue 9, 2006, Pages 1259-1271

  Li, Jian ^a   Tan, Jin Zhi ^a   Chen, Li Li ^a   Zhang, Jian ^a   Shen, Xu ^a,b   Mei, Chang Lin ^c   Fu, Li Li ^c   Lin, Li Ping ^a   Ding, Jian ^a   Xiong, Bing ^a   Xiong, Xi Shan ^c   Liu, Hong ^a   Luo, Xiao Min ^a   Jiang, Hua Liang ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor; N substituted thiourea derivatives; SPAC1; Tyrosine kinase inhibitor; Virtual screening

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; THIOUREA DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LUNG ADENOCARCINOMA; SURFACE PLASMON RESONANCE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; PROTEIN-TYROSINE KINASES; THIOUREA;

EID: 33748765547     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00437.x     Document Type: Article

References (45)

1. Aaronson SA. Growth factors and cancer. Science 1991; 254: 1146-52.
2. Bridges AJ. Chemical inhibitors of protein kinases. Chem Rev 2001; 101: 2541-72.
3. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-12.
4. Elder JT, Fisher GJ, Lindquist PB, Bennett GL, Pittelkow MR, Coffey RJ, et al. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 1989; 243: 811-4.
5. Yang EB, Guo YJ, Zhang K, Chen YZ, Mack P. Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives. Biochim Biophys Acta 2001; 1550: 144-52.
6. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001; 21: 499-512.
7. Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, et al. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 1997; 40: 3601-16.
8. Khazaie K, Shirrmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metast Rev 1993; 12: 155-274.
9. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994; 265: 1093-5.
10. Chinkers M, Brugge JS. Characterization of structural domains of the human epidermal growth factor receptor obtained by partial proteolysis. J Biol Chem 1984; 259: 11 534-42.
11. Carpenter CD, Ingraham HA, Cochet C, Walton GM, Lazar CS, Sowadski JM, et al. Structural analysis of the transmembrane domain of the epidermal growth factor receptor. J Biol Chem 1991; 266: 5750-5.
12. Araujo RP, Petricoin EF, Liotta LA. A mathematical model of combination therapy using the EGFR signaling networ k. Biosystems 2005; 80: 57-9.
13. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem 2003; 46: 49-63.
14. Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, Ye F, et al. 6-Substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J Med Chem 2001; 44: 2719-34.
15. Mu F, Coffing SL, Riese DJ, Geahlen RL, Verdier-Pinard P, Hamel TE, et al. Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization. J Med Chem 2001; 44: 441-52.
16. Jin Y, Li HY, Lin LP, Tan J, Ding J, Luo X, et al. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors. Bioorg Med Chem 2005; 13: 5613-22.
17. Albuschat R, Löwe W, Weber M, Luger P, Jendrossek V. 4-Anilinoquinazolines with lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties. Eur J Med Chem 2004; 39: 1001-11.
18. Asano T, Yoshikawa T, Usui T, Yamamoto H, Yamamoto Y, Uehara Y, et al. Benzamides and benzamidines as specific inhibitors of epidermal growth factor receptor and v-Src protein tyrosine kinases. Bioorg Med Chem 2004; 12: 3529-42.
19. Supuran CT, Scozzafava A. Protein tyrosine kinase inhibitors as anticancer agents. Expert Opin Ther Patents 2004; 14: 35-53.
20. Chen G, Luo X, Zhu W, Luo C, Liu H, Puah CM, et al. Elucidating inhibitory models of the inhibitors of epidermal growth factor receptor by docking and 3D-QSAR. Bioorg Med Chem 2004; 12: 2409-17.
21. Norman P. ZD-1839 (astraZeneca). Curr Opin Investig Drugs 2001; 3: 428-34.
22. Norman P. OSI-774 OSI pharmaceuticals. Curr Opin Investig Drugs 2001; 2: 298-304.
23. Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, et al. Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem 1999; 42: 1803-15.
24. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998; 95: 12022-7.
25. Wissner A, Johnson BD, Floyd MB, Kitchen DB, inventors; American Cyanamid Company, assignee. 4-Aminoquinazolines as EGFR inhibitors. US Patent 5 760 041. 1998; Jun 2.
26. Lee MW, Seo CW, Kim SW, Yang HJ, Lee HW, Choi JH, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004; 84: 23-6.
27. Kuntz ID, Meng EC, Shoichet BK. Receptor-based molecular design. Acc Chem Res 1994; 27: 117-23.
28. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124-9.
29. Liu H, Li Y, Song M, Tan X, Cheng F, Zheng S, et al. Structure-based discovery of potassium channel blockers from natural products: Virtual screening and electrophysiological assay testing. Chem Biol 2003; 10: 1103-13.
30. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002; 277: 46 265-72.
31. Li J, Chen J, Gui C, Zhang L, Qin Y, Xu Q, et al. Discovering novel chemical inhibitors of human cyclophilin A: virtual screening, synthesis, and bioassay. Bioorg Med Chem 2006; 14: 2209-24.
32. Ewing T, Kuntz ID. Critical evaluation of search algorithms used in automated molecular docking. J Comput Chem 1997; 18: 1175-89.
33. Kuntz ID. Structure-based strategies for drug design and discovery. Science 1992; 257: 1078-82.
34. Weiner SJ, Kollman PA, Nguyen DT, Case DA. An all atom force field for simulations of proteins and nucleic acids. J Comput Chem 1986; 7: 230-52.
35. Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity-A rapid access to atomic charges. Tetrahedron 1980; 36: 3219-28.
36. Muegge I, Rarey M. Small molecule docking and scoring. In: Lipkowitz KB, Boyd DB, editors. Reviews in computational chemistry.. New York: John Wiley & Sons; 2001. p 1-60.
37. Charifson PS, Corkery JJ, Murcko MA, Walters WP. Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem 1999; 42: 5100-9.
38. Sybyl molecular modeling package (Computer program). Version 6.8. St Louis, MO: Tripos Associates, 2000.
39. Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. J Pharm Belg 1997; 52: 88-96.
40. Meth-Cohn O, Narine B, Tarnowski B. A versatile new synthesis of quinolines and related fused pyridines. Part 5. The synthesis of 2-chloroquinoline-3-carbaldehydes. J Chem Soc Perkin Trans 1 1981; 5: 1520-30.
41. Meth-Cohn O, Narine B, Tarnowski B, Hayes R, Keyzad A, Rhouati S, et al. A versatile new synthesis of quinolines and related fused pyridines. Part 9. Synthetic application of the 2-chloroquinoline-3-carbaldehydes. J Chem Soc Perkin Trans 1 1981; 9: 2509-17.
42. Tilakraj T, Ambekar SY. Synthesis and mass spectra of some 2H-pyrano[2,3-b]quinolin-2-ones. J Indian Chem Soc 1985; 62: 251-3.
43. Guo XN, Zhong L, Zhang XH, Zhao WM, Zhang XW, Lin LP, et al. Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Biochim Biophys Acta 2004; 1673: 186-93.
44. Sargent JM, Taylor CG. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br J Cancer 1989; 60: 206-10.
45. Rewcastle GW, Denny WA, Bridges AJ, Zhou H, Cody DR, McMichael A, et al. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem 1995; 38: 3482-7.